Crossbow announced it raised $77 million in a Series B financing that will advance the development of TCR-mimetic antibody ...
Foundational research led by co-founder Justin Eyquem, Ph.D., underpins Azalea’s proprietary in vivo CAR T platformPeer-reviewed publication ...
T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on ...
T Cells Gain Phagocytic Function via Specific Antigen RecognitionThe research team engineered CD8+ Jurkat T cells to express SVAR16 ...
Immatics N.V., a clinical-stage biopharmaceutical company, announced that it will present data on its lead cell therapy candidate, IMA203 TCR T-cell therapy targeting PRAME, at the upcoming 2025 ASCO ...
Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced a collaboration ...
Advances in cell and gene therapy have led to U.S. Food and Drug Administration approved adoptive cell therapies to treat hematological malignancies and solid tumors. There is great enthusiasm in the ...
Captain T Cell GmbH has successfully closed an equity financing round to support its T-cell receptor (TCR) T-cell therapies for solid tumors. The company’s autologous lead program, CTC-127, is a ...
Enara Bio, a pioneer in Dark Antigen(R) discovery and bispecific T cell engager innovation, today announced new data to be presented at the American Association for Cancer Research (AACR) Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results